CannTab Therapeutics Ltd (CNSX:PILL) Hard Pill Formulation is Patentable, Novel and Useful

CannTab Therapeutics Ltd (CSE:PILL) (OTCMKTS:CTABF) (FRA:TBF1) CFO Richard Goldstein visits Midas Letter Studios to discuss the recent stock surge and latest company developments. CannTab is a solid oral-dose tablet company, which started in the pharma business and then adapted its technologies to the cannabis space almost four years ago. The stock jumped as high as 98 percent and closed up 62.5 percent from the previous days closing price. The CFO explains “we had the little flurry of activity; we hope to have more trading and more interest behind the stock. We’re getting more eyeballs, and taking advantage of all our hard work.” CannTab recently graduated on the OTC to the QX listing making it easier for US investors to take ownership of the company. Mr. Goldstein believes tablets are truly the medical answer. The company’s bi-layered tablet, which are scheduled to be going into clinical trials soon, combine immediate release and extended release properties, using both CBD and THC. Additionally, the hard pill received an initial assessment from the Geneva-based International Preliminary Report on Patentability indicating the formulation is novel, non-obvious and useful.

Original article: CannTab Therapeutics Ltd (CNSX:PILL) Hard Pill Formulation is Patentable, Novel and Useful

©2019 Midas Letter. All Rights Reserved.